EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Low screening rates and high prevalence of osteoporosis in cirrhosis: A real‐world retrospective analysis

Mary Thomson iD, Adam Scott, Suzanne Trost, Jack Lake, Nicholas Lim

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17823 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Mary Thomson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Esophageal and Gastric Varices, Osteoporosis, Bone Diseases, Metabolic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: American Association for the Study of Liver Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with cirrhosis are at increased risk for osteoporosis, and those who suffer a fracture are at high risk for mortality. Despite this, osteoporosis is often overlooked and undertreated. This study aimed to evaluate osteoporosis screening, management, and adverse osteoporosis medication events in patients with cirrhosis.

Methods

We performed a retrospective chart review of adult outpatients with compensated and decompensated cirrhosis seen in single health system over a 6‐year period. Patient demographics, liver and bone health comorbidities, DEXA scan results, and medications were abstracted.

Results

In total, 5398 patients met criteria. The cohort was predominately white (79.1%) and older (age 59). 44.4% were female. 64.6% had decompensated cirrhosis. Median MELD‐Na score was 12.8. 23.5% had a DEXA scan ordered, approximately 50% completed this test. Patients who were older, female, white, with more severe liver disease, and other osteoporosis risk factors were more likely to have a DEXA scan ordered. 48.5% of patients had osteopenia and 30.2% had osteoporosis on DEXA scan. Only 22.6% of patients with osteoporosis received treatment, most commonly oral bisphosphonates. Oral bisphosphonate prescription was not associated with variceal bleeding (8.4% without vs. 4.8% with, p = 0.487).

Conclusion

A minority of patients with cirrhosis were screened for osteoporosis. The majority screened had osteopenia or osteoporosis on DEXA scan. Less than a quarter of patients with osteoporosis were started on treatment. Real‐world experience of oral bisphosphonate use did not reveal higher rates of gastrointestinal bleeding. There is room for improvement in all aspects of bone health care in cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal and Gastric VaricesOsteoporosisBone Diseases, MetabolicAdultHumansFemaleMiddle AgedMaleRetrospective StudiesPrevalenceAbsorptiometry, PhotonGastrointestinal HemorrhageDiphosphonatesLiver Cirrhosis

Substanzen

Diphosphonates

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.
  • University of Minnesota Medical School, Minneapolis, Minnesota, USA.
  • Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Mary Thomson

Förderung

  • American Association for the Study of Liver Diseases

Zitieren

APA

Thomson, M., Scott, A., Trost, S., Lake, J., & Lim, N. (2024). Low screening rates and high prevalence of osteoporosis in cirrhosis: A real‐world retrospective analysis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17823

Vancouver

Thomson M, Scott A, Trost S, Lake J, Lim N. Low screening rates and high prevalence of osteoporosis in cirrhosis: A real‐world retrospective analysis. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17823

BibTeX
@article{Thomson2024,
  author = {Thomson, Mary and Scott, Adam and Trost, Suzanne and Lake, Jack and Lim, Nicholas},
  title = {Low screening rates and high prevalence of osteoporosis in cirrhosis: A real‐world retrospective analysis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17823}
}
Kostenlos starten →